German radiopharma Ariceum unveils early efficacy signal for lead asset in neuroendocrine cancers

28 Sep 2023

OligonucleotideClinical Study

Berlin-based Ariceum Therapeutics has revealed positive data from a Phase I/II trial of its radiopharmaceutical therapy, satoreotide, in neuroendocrine tumors, two years after the biotech made its debut. Satoreotide uses the radioactive isotope lutetium to antagonize the somatostatin receptor 2 (SSTR2). Ariceum launched in 2021 after acquiring full rights to satoreotide from Ipsen. The Phase I/II trial studied satoreotide in people with previously treated, progressive SSTR2-positive NETs SSTR2-positive NETs. The trial’s part A comprised 15 patients who completed three cycles of satoreotide at a fixed activity level, while part B included 25 patients who got one to five cycles of the therapy at different activity levels.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Ariceum Therapeutics GmbH

Ipsen SA

Indications

Neuroendocrine TumorsSSTR2 positive Gastro-Enteropancreatic Neuroendocrine Tumor

Targets

SSTR2

Drugs

177Lu-Satoreotide tetraxetanLutetium (177 Lu) Chloride

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.